Have a feature idea you'd love to see implemented?
Let us know!
VIRX Viracta Therapeutics Inc
Price (delayed)
$0.2427
Market cap
$9.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.16
Enterprise value
$14.4M
Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination
Highlights
The company's debt fell by 26% YoY
VIRX's EPS is up by 16% YoY and by 6% from the previous quarter
The equity has plunged by 93% YoY and by 76% from the previous quarter
The quick ratio has dropped by 78% year-on-year and by 20% since the previous quarter
Key stats
What are the main financial stats of VIRX
Market
Valuations
Earnings
Shares outstanding
39.42M
Market cap
$9.57M
Enterprise value
$14.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$41.88M
EBITDA
-$41.42M
Free cash flow
-$38.19M
Per share
Balance sheet
Liquidity
EPS
-$1.16
Free cash flow per share
-$0.97
Book value per share
$0.07
Revenue per share
$0
TBVPS
$0.79
Total assets
$31.32M
Total liabilities
$28.65M
Debt
$18.82M
Equity
$2.67M
Working capital
$2.42M
Debt to equity
7.05
Current ratio
1.08
Quick ratio
1.05
Net debt/EBITDA
-0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-92.6%
Return on equity
-292.1%
Return on invested capital
-168.1%
Return on capital employed
-1,567.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIRX stock price
How has the Viracta Therapeutics stock price performed over time
Intraday
-0.12%
1 week
8.93%
1 month
7.87%
1 year
-65.38%
YTD
-57.42%
QTD
4.88%
Financial performance
How have Viracta Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.5M
Net income
-$45.34M
Gross margin
N/A
Net margin
N/A
The net income has grown by 14% YoY and by 6% from the previous quarter
The operating income is up by 9% year-on-year and by 5% since the previous quarter
Growth
What is Viracta Therapeutics's growth rate over time
Valuation
What is Viracta Therapeutics stock price valuation
P/E
N/A
P/B
3.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VIRX's EPS is up by 16% YoY and by 6% from the previous quarter
The equity has plunged by 93% YoY and by 76% from the previous quarter
The stock's price to book (P/B) is 70% more than its 5-year quarterly average of 2.1 and 2% more than its last 4 quarters average of 3.5
Efficiency
How efficient is Viracta Therapeutics business performance
The return on invested capital has dropped by 135% year-on-year and by 57% since the previous quarter
The ROE has plunged by 52% from the previous quarter
The return on assets has declined by 50% year-on-year and by 16% since the previous quarter
Dividends
What is VIRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIRX.
Financial health
How did Viracta Therapeutics financials performed over time
The company's total assets is 9% higher than its total liabilities
VIRX's current ratio has dropped by 78% year-on-year and by 20% since the previous quarter
The quick ratio has dropped by 78% year-on-year and by 20% since the previous quarter
The equity has plunged by 93% YoY and by 76% from the previous quarter
The company's debt fell by 26% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.